Skip to content

CLINICAL EDUCATION AND RESOURCES

These educational resources are provided to you through partnerships with other educational organizations and are not AVAHO-developed education.

Project VA-ECHO

240ppi logo transparent oval

What is VA-ECHO?

Specialty Care Veterans Administration Extension for Community Healthcare Outcomes (VA-ECHO) is a national accredited continuing education program.

  • VA-ECHO cultivates a learning community through mentorship by promoting
    evidence-based, Veteran-centered, and team-based care in more than 25
    specialties.
  • Our program offers a wide variety of accredited continuing education (CE) credits
    options (up to 18 types) including, but not limited to: AAPA, ACCME, ACCME-NP,
    ACPE, ANCC, ASWB, NYSEDSW, & JA-IPCE.

SharePoint Page:

Specialty Care VA-ECHO - Home (sharepoint.com)

Individuals can join our Listserv(s) here:

VA-ECHO (iths.org)

Clinical Pathways

The National Oncology Program Office has developed disease-specific Clinical Pathway tools for clinicians to use that map out evidence-based treatment courses.

These clinical support tools provide clinicians with guidance that ensure standardized, high-quality care for our Veterans living with a cancer diagnosis.

  • The pathways were developed by a team of multidisciplinary subject matter experts and national guidelines: offering guidance for both common and rare cancers.
  • The pathways differ from other national guidelines, as they take into consideration treatment efficacy, toxicity, and cost.
  • Use of the pathways also ensures access and equality of care, no matter where the receives cancer care.

Visit the VA Clinical Pathways page for more information.

Ongoing Opportunities

The following opportunities are available at your convenience (see dates for start/end availability).

Bladder Cancer: Assessing and Incorporating Novel Treatment Strategies (a Prime partner opportunity)
0.5 CME/CE
Available through January 11, 2025

 

Elevating Care Coordination for Timely Management of Follicular Lymphoma (a Prime Partner opportunity)
0.5 CME/CE
Available through December 20, 2024

Scroll To Top